JP2011527675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527675A5 JP2011527675A5 JP2011517424A JP2011517424A JP2011527675A5 JP 2011527675 A5 JP2011527675 A5 JP 2011527675A5 JP 2011517424 A JP2011517424 A JP 2011517424A JP 2011517424 A JP2011517424 A JP 2011517424A JP 2011527675 A5 JP2011527675 A5 JP 2011527675A5
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- optionally substituted
- independently selected
- hydroxy
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003545 alkoxy group Chemical group 0.000 claims description 327
- 125000003118 aryl group Chemical group 0.000 claims description 320
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 306
- 125000001424 substituent group Chemical group 0.000 claims description 266
- 229910052736 halogen Inorganic materials 0.000 claims description 256
- 150000002367 halogens Chemical group 0.000 claims description 253
- 125000000217 alkyl group Chemical group 0.000 claims description 233
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 208
- 125000001072 heteroaryl group Chemical group 0.000 claims description 181
- 229910052739 hydrogen Inorganic materials 0.000 claims description 166
- 239000001257 hydrogen Substances 0.000 claims description 166
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 102
- 125000000623 heterocyclic group Chemical group 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 74
- 125000001931 aliphatic group Chemical group 0.000 claims description 64
- -1 heteroaliphatic Chemical group 0.000 claims description 60
- 229910052760 oxygen Inorganic materials 0.000 claims description 60
- 229910052717 sulfur Inorganic materials 0.000 claims description 60
- 125000002723 alicyclic group Chemical group 0.000 claims description 57
- 125000005842 heteroatom Chemical group 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000002619 bicyclic group Chemical group 0.000 claims description 48
- 150000002431 hydrogen Chemical group 0.000 claims description 42
- 229910052757 nitrogen Inorganic materials 0.000 claims description 42
- 210000000056 organ Anatomy 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 35
- 206010016654 Fibrosis Diseases 0.000 claims description 35
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 28
- 230000004761 fibrosis Effects 0.000 claims description 27
- 101150065749 Churc1 gene Proteins 0.000 claims description 26
- 102100038239 Protein Churchill Human genes 0.000 claims description 26
- 208000027418 Wounds and injury Diseases 0.000 claims description 25
- 206010063837 Reperfusion injury Diseases 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 230000000302 ischemic effect Effects 0.000 claims description 24
- 239000007909 solid dosage form Substances 0.000 claims description 24
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 24
- 229920002554 vinyl polymer Polymers 0.000 claims description 24
- 208000031225 myocardial ischemia Diseases 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 22
- 239000000651 prodrug Substances 0.000 claims description 22
- 229940002612 prodrug Drugs 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 230000006378 damage Effects 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 208000014674 injury Diseases 0.000 claims description 17
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 16
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 201000006370 kidney failure Diseases 0.000 claims description 16
- 201000006938 muscular dystrophy Diseases 0.000 claims description 16
- 206010061481 Renal injury Diseases 0.000 claims description 15
- 208000028867 ischemia Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 12
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 12
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims description 12
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 229940068968 polysorbate 80 Drugs 0.000 claims description 12
- 210000004204 blood vessel Anatomy 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- 210000003734 kidney Anatomy 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- 238000002054 transplantation Methods 0.000 claims description 10
- 206010052428 Wound Diseases 0.000 claims description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 9
- 210000000013 bile duct Anatomy 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 208000007848 Alcoholism Diseases 0.000 claims description 8
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 8
- 208000015163 Biliary Tract disease Diseases 0.000 claims description 8
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 8
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 8
- 208000018565 Hemochromatosis Diseases 0.000 claims description 8
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims description 8
- 208000005331 Hepatitis D Diseases 0.000 claims description 8
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 8
- 208000018839 Wilson disease Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 206010008118 cerebral infarction Diseases 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 8
- 210000002216 heart Anatomy 0.000 claims description 8
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 230000002107 myocardial effect Effects 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 238000010606 normalization Methods 0.000 claims description 8
- 230000010412 perfusion Effects 0.000 claims description 8
- 239000002953 phosphate buffered saline Substances 0.000 claims description 8
- 230000002685 pulmonary effect Effects 0.000 claims description 8
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 8
- 239000004575 stone Substances 0.000 claims description 8
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 7
- 206010053648 Vascular occlusion Diseases 0.000 claims description 7
- 230000033115 angiogenesis Effects 0.000 claims description 7
- 208000002672 hepatitis B Diseases 0.000 claims description 7
- 208000016245 inborn errors of metabolism Diseases 0.000 claims description 7
- 208000015978 inherited metabolic disease Diseases 0.000 claims description 7
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 7
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 7
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000005176 Hepatitis C Diseases 0.000 claims description 5
- 230000035876 healing Effects 0.000 claims description 5
- 208000037806 kidney injury Diseases 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 5
- 201000002793 renal fibrosis Diseases 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 4
- 206010056328 Hepatic ischaemia Diseases 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000002872 contrast media Substances 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000012208 gluconic acid Nutrition 0.000 claims description 4
- 239000000174 gluconic acid Substances 0.000 claims description 4
- 229950006191 gluconic acid Drugs 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 229940099563 lactobionic acid Drugs 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- VWESQMOYFHDJMO-SNAWJCMRSA-N (6-chloropyridin-3-yl)-[3-[(e)-2-thiophen-2-ylethenyl]pyrazol-1-yl]methanone Chemical compound C1=NC(Cl)=CC=C1C(=O)N1N=C(\C=C\C=2SC=CC=2)C=C1 VWESQMOYFHDJMO-SNAWJCMRSA-N 0.000 claims description 2
- ROAIMWPBGVEJLH-SOFGYWHQSA-N (6-morpholin-4-ylpyridin-3-yl)-[3-[(e)-2-phenylethenyl]pyrazol-1-yl]methanone Chemical compound C1=CC(\C=C\C=2C=CC=CC=2)=NN1C(=O)C(C=N1)=CC=C1N1CCOCC1 ROAIMWPBGVEJLH-SOFGYWHQSA-N 0.000 claims description 2
- ACMPNFSQDDTAIB-SNAWJCMRSA-N 1,3-benzodioxol-5-yl-[3-[(e)-2-(furan-2-yl)ethenyl]pyrazol-1-yl]methanone Chemical compound C=1C=C2OCOC2=CC=1C(=O)N(N=1)C=CC=1\C=C\C1=CC=CO1 ACMPNFSQDDTAIB-SNAWJCMRSA-N 0.000 claims description 2
- ADAKSJMCFLSJDL-SNAWJCMRSA-N 1,3-benzodioxol-5-yl-[3-[(e)-2-thiophen-2-ylethenyl]pyrazol-1-yl]methanone Chemical compound C=1C=C2OCOC2=CC=1C(=O)N(N=1)C=CC=1\C=C\C1=CC=CS1 ADAKSJMCFLSJDL-SNAWJCMRSA-N 0.000 claims description 2
- PBSKHGYZCGLRMW-SNAWJCMRSA-N 1-[4-[3-[(e)-2-thiophen-2-ylethenyl]pyrazole-1-carbonyl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(=O)N1N=C(\C=C\C=2SC=CC=2)C=C1 PBSKHGYZCGLRMW-SNAWJCMRSA-N 0.000 claims description 2
- PVFHXSKBMLKNOI-BQYQJAHWSA-N 2-(4-chlorophenyl)-1-[3-[(e)-2-thiophen-2-ylethenyl]pyrazol-1-yl]ethanone Chemical compound C1=CC(Cl)=CC=C1CC(=O)N1N=C(\C=C\C=2SC=CC=2)C=C1 PVFHXSKBMLKNOI-BQYQJAHWSA-N 0.000 claims description 2
- HWLXDCWWKCZSLC-JXMROGBWSA-N 2-(4-methoxyphenyl)-1-[3-[(e)-2-phenylethenyl]pyrazol-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)N1N=C(\C=C\C=2C=CC=CC=2)C=C1 HWLXDCWWKCZSLC-JXMROGBWSA-N 0.000 claims description 2
- SCDNPHPQYKUMQW-AATRIKPKSA-N 2-[(E)-2-(1H-pyrazol-5-yl)ethenyl]-1H-indole Chemical compound C=1C2=CC=CC=C2NC=1\C=C\C=1C=CNN=1 SCDNPHPQYKUMQW-AATRIKPKSA-N 0.000 claims description 2
- SCDNPHPQYKUMQW-WAYWQWQTSA-N 2-[(Z)-2-(1H-pyrazol-5-yl)ethenyl]-1H-indole Chemical compound C=1C2=CC=CC=C2NC=1/C=C\C=1C=CNN=1 SCDNPHPQYKUMQW-WAYWQWQTSA-N 0.000 claims description 2
- OAHIEMNLLAWRLZ-VOTSOKGWSA-N 3-[3-[(E)-2-(1H-pyrrol-2-yl)ethenyl]pyrazol-1-yl]benzonitrile Chemical compound N#CC1=CC=CC(N2N=C(\C=C\C=3NC=CC=3)C=C2)=C1 OAHIEMNLLAWRLZ-VOTSOKGWSA-N 0.000 claims description 2
- NQDNQIKHDMEMDL-SNAWJCMRSA-N 3-[3-[(E)-2-(1H-pyrrol-3-yl)ethenyl]pyrazole-1-carbonyl]benzonitrile Chemical compound C1=CC(\C=C\C2=CNC=C2)=NN1C(=O)C1=CC=CC(C#N)=C1 NQDNQIKHDMEMDL-SNAWJCMRSA-N 0.000 claims description 2
- LVOFZXYKYGTEMU-SNAWJCMRSA-N 3-[3-[(e)-2-(furan-3-yl)ethenyl]pyrazole-1-carbonyl]benzonitrile Chemical compound C1=CC(\C=C\C2=COC=C2)=NN1C(=O)C1=CC=CC(C#N)=C1 LVOFZXYKYGTEMU-SNAWJCMRSA-N 0.000 claims description 2
- LIQIDBDGLKJLBP-VOTSOKGWSA-N 3-[3-[(e)-2-thiophen-2-ylethenyl]pyrazole-1-carbonyl]benzonitrile Chemical compound C1=CC(\C=C\C=2SC=CC=2)=NN1C(=O)C1=CC=CC(C#N)=C1 LIQIDBDGLKJLBP-VOTSOKGWSA-N 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- ZIEVRTDKRHVCJQ-BQYQJAHWSA-N 4-[3-[(e)-2-thiophen-2-ylethenyl]pyrazole-1-carbonyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)N1N=C(\C=C\C=2SC=CC=2)C=C1 ZIEVRTDKRHVCJQ-BQYQJAHWSA-N 0.000 claims description 2
- JVTDKYFPSWGHIV-BQYQJAHWSA-N 4-[3-[(e)-2-thiophen-2-ylethenyl]pyrazole-1-carbonyl]benzonitrile Chemical compound C1=CC(\C=C\C=2SC=CC=2)=NN1C(=O)C1=CC=C(C#N)C=C1 JVTDKYFPSWGHIV-BQYQJAHWSA-N 0.000 claims description 2
- RYTGQEUHMMXXMN-ONEGZZNKSA-N 5-[(E)-2-(1H-pyrrol-2-yl)ethenyl]-1H-pyrazole Chemical compound C1=CNN=C1/C=C/C1=CC=CN1 RYTGQEUHMMXXMN-ONEGZZNKSA-N 0.000 claims description 2
- QNQPCKJLSXTOPS-OWOJBTEDSA-N 5-[(E)-2-(1H-pyrrol-3-yl)ethenyl]-1H-pyrazole Chemical compound C1=CNC=C1/C=C/C=1C=CNN=1 QNQPCKJLSXTOPS-OWOJBTEDSA-N 0.000 claims description 2
- RYTGQEUHMMXXMN-ARJAWSKDSA-N 5-[(Z)-2-(1H-pyrrol-2-yl)ethenyl]-1H-pyrazole Chemical compound C1=CNN=C1/C=C\C1=CC=CN1 RYTGQEUHMMXXMN-ARJAWSKDSA-N 0.000 claims description 2
- QNQPCKJLSXTOPS-UPHRSURJSA-N 5-[(Z)-2-(1H-pyrrol-3-yl)ethenyl]-1H-pyrazole Chemical compound C1=CNC=C1/C=C\C=1C=CNN=1 QNQPCKJLSXTOPS-UPHRSURJSA-N 0.000 claims description 2
- WTLCERBYPIMJNW-SNAWJCMRSA-N 5-[(e)-2-(2,6-dichlorophenyl)ethenyl]-1h-pyrazole Chemical compound ClC1=CC=CC(Cl)=C1\C=C\C1=CC=NN1 WTLCERBYPIMJNW-SNAWJCMRSA-N 0.000 claims description 2
- FSONDHSXOHJMCO-GORDUTHDSA-N 5-[(e)-2-(4-methoxyphenyl)ethenyl]-1h-pyrazole Chemical compound C1=CC(OC)=CC=C1\C=C\C1=NNC=C1 FSONDHSXOHJMCO-GORDUTHDSA-N 0.000 claims description 2
- YKUVDPWPDNKMPQ-OWOJBTEDSA-N 5-[(e)-2-(5-nitrofuran-2-yl)ethenyl]-1h-pyrazole Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C1=NNC=C1 YKUVDPWPDNKMPQ-OWOJBTEDSA-N 0.000 claims description 2
- JJZCXCVBDQAHLT-OWOJBTEDSA-N 5-[(e)-2-(furan-3-yl)ethenyl]-1h-pyrazole Chemical compound C1=COC=C1/C=C/C=1C=CNN=1 JJZCXCVBDQAHLT-OWOJBTEDSA-N 0.000 claims description 2
- NFLQSIIRRGMWIY-VOTSOKGWSA-N 5-[(e)-2-phenylethenyl]-1h-pyrazole Chemical compound C1=CNN=C1/C=C/C1=CC=CC=C1 NFLQSIIRRGMWIY-VOTSOKGWSA-N 0.000 claims description 2
- SVGZNMNPBUUXQL-OWOJBTEDSA-N 5-[(e)-2-thiophen-3-ylethenyl]-1h-pyrazole Chemical compound C1=CSC=C1/C=C/C=1C=CNN=1 SVGZNMNPBUUXQL-OWOJBTEDSA-N 0.000 claims description 2
- WTLCERBYPIMJNW-PLNGDYQASA-N 5-[(z)-2-(2,6-dichlorophenyl)ethenyl]-1h-pyrazole Chemical compound ClC1=CC=CC(Cl)=C1\C=C/C1=NNC=C1 WTLCERBYPIMJNW-PLNGDYQASA-N 0.000 claims description 2
- FSONDHSXOHJMCO-DJWKRKHSSA-N 5-[(z)-2-(4-methoxyphenyl)ethenyl]-1h-pyrazole Chemical compound C1=CC(OC)=CC=C1\C=C/C1=NNC=C1 FSONDHSXOHJMCO-DJWKRKHSSA-N 0.000 claims description 2
- YKUVDPWPDNKMPQ-UPHRSURJSA-N 5-[(z)-2-(5-nitrofuran-2-yl)ethenyl]-1h-pyrazole Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C/C1=NNC=C1 YKUVDPWPDNKMPQ-UPHRSURJSA-N 0.000 claims description 2
- HYJHSSBFLWWIIS-VURMDHGXSA-N 5-[(z)-2-naphthalen-2-ylethenyl]-1h-pyrazole Chemical compound C=1C=C2C=CC=CC2=CC=1/C=C\C=1C=CNN=1 HYJHSSBFLWWIIS-VURMDHGXSA-N 0.000 claims description 2
- NFLQSIIRRGMWIY-SREVYHEPSA-N 5-[(z)-2-phenylethenyl]-1h-pyrazole Chemical compound C1=CNN=C1/C=C\C1=CC=CC=C1 NFLQSIIRRGMWIY-SREVYHEPSA-N 0.000 claims description 2
- SVGZNMNPBUUXQL-UPHRSURJSA-N 5-[(z)-2-thiophen-3-ylethenyl]-1h-pyrazole Chemical compound C1=CSC=C1/C=C\C=1C=CNN=1 SVGZNMNPBUUXQL-UPHRSURJSA-N 0.000 claims description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 2
- TZTVBBLETXICAZ-FLIBITNWSA-N N1(N=CC=C1)\C=C/C1=CC=C(N(C)C)C=C1 Chemical compound N1(N=CC=C1)\C=C/C1=CC=C(N(C)C)C=C1 TZTVBBLETXICAZ-FLIBITNWSA-N 0.000 claims description 2
- 241000750042 Vini Species 0.000 claims description 2
- MRKQFTGFBWZIIP-VOTSOKGWSA-N [3-[(e)-2-(2,6-dichlorophenyl)ethenyl]pyrazol-1-yl]-thiophen-2-ylmethanone Chemical compound ClC1=CC=CC(Cl)=C1\C=C\C1=NN(C(=O)C=2SC=CC=2)C=C1 MRKQFTGFBWZIIP-VOTSOKGWSA-N 0.000 claims description 2
- QXVFVWIMRPHTFC-VOTSOKGWSA-N [3-[(e)-2-(furan-2-yl)ethenyl]pyrazol-1-yl]-(1-methylpyrrol-2-yl)methanone Chemical compound CN1C=CC=C1C(=O)N1N=C(\C=C\C=2OC=CC=2)C=C1 QXVFVWIMRPHTFC-VOTSOKGWSA-N 0.000 claims description 2
- CYHRNLURSDBGLN-BQYQJAHWSA-N [3-[(e)-2-(furan-2-yl)ethenyl]pyrazol-1-yl]-[2-(trifluoromethoxy)phenyl]methanone Chemical compound FC(F)(F)OC1=CC=CC=C1C(=O)N1N=C(\C=C\C=2OC=CC=2)C=C1 CYHRNLURSDBGLN-BQYQJAHWSA-N 0.000 claims description 2
- WEFGSSQTJDPWNR-VOTSOKGWSA-N [3-[(e)-2-(furan-2-yl)ethenyl]pyrazol-1-yl]-[3-(trifluoromethoxy)phenyl]methanone Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2N=C(\C=C\C=3OC=CC=3)C=C2)=C1 WEFGSSQTJDPWNR-VOTSOKGWSA-N 0.000 claims description 2
- KLTFETJTDIMBNH-VOTSOKGWSA-N [3-[(e)-2-thiophen-2-ylethenyl]pyrazol-1-yl]-[3-(trifluoromethoxy)phenyl]methanone Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2N=C(\C=C\C=3SC=CC=3)C=C2)=C1 KLTFETJTDIMBNH-VOTSOKGWSA-N 0.000 claims description 2
- YSSMEIBEBGDNBB-VMPITWQZSA-N [3-[(e)-2-thiophen-2-ylethenyl]pyrazol-1-yl]-[4-(trifluoromethoxy)phenyl]methanone Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)N1N=C(\C=C\C=2SC=CC=2)C=C1 YSSMEIBEBGDNBB-VMPITWQZSA-N 0.000 claims description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 2
- HMHVZNTXXDQCGW-CMDGGOBGSA-N cyclohexyl-[3-[(e)-2-thiophen-2-ylethenyl]pyrazol-1-yl]methanone Chemical compound C1=CC(\C=C\C=2SC=CC=2)=NN1C(=O)C1CCCCC1 HMHVZNTXXDQCGW-CMDGGOBGSA-N 0.000 claims description 2
- ATYFLPYBMPJORO-RMKNXTFCSA-N cyclopropyl-[3-[(e)-2-phenylethenyl]pyrazol-1-yl]methanone Chemical compound C1=CC(\C=C\C=2C=CC=CC=2)=NN1C(=O)C1CC1 ATYFLPYBMPJORO-RMKNXTFCSA-N 0.000 claims description 2
- TWGYAOVYFJAKQX-ZZXKWVIFSA-N n,n-dimethyl-4-[(e)-2-(1h-pyrazol-5-yl)ethenyl]aniline Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=NNC=C1 TWGYAOVYFJAKQX-ZZXKWVIFSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- HCXZIRNJISTLKL-CMDGGOBGSA-N phenyl-[3-[(e)-2-thiophen-2-ylethenyl]pyrazol-1-yl]methanone Chemical compound C1=CC(\C=C\C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 HCXZIRNJISTLKL-CMDGGOBGSA-N 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims 8
- 231100000283 hepatitis Toxicity 0.000 claims 8
- 101710081722 Antitrypsin Proteins 0.000 claims 6
- 208000006011 Stroke Diseases 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 230000001475 anti-trypsic effect Effects 0.000 claims 6
- 230000007812 deficiency Effects 0.000 claims 6
- 239000002753 trypsin inhibitor Substances 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 208000037262 Hepatitis delta Diseases 0.000 claims 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 230000008081 blood perfusion Effects 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 201000010901 lateral sclerosis Diseases 0.000 claims 3
- 208000005264 motor neuron disease Diseases 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 4
- 0 *C(*)(CC1)CCC1C=C[C@@]1NNC=C1 Chemical compound *C(*)(CC1)CCC1C=C[C@@]1NNC=C1 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UJUYXPRUYHXIFR-SNAWJCMRSA-N 3-[3-[(e)-2-thiophen-3-ylethenyl]pyrazole-1-carbonyl]benzonitrile Chemical compound C1=CC(\C=C\C2=CSC=C2)=NN1C(=O)C1=CC=CC(C#N)=C1 UJUYXPRUYHXIFR-SNAWJCMRSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13448508P | 2008-07-10 | 2008-07-10 | |
| US61/134,485 | 2008-07-10 | ||
| PCT/US2009/004014 WO2010005580A2 (en) | 2008-07-10 | 2009-07-09 | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012415A Division JP2015108002A (ja) | 2008-07-10 | 2015-01-26 | 肝細胞増殖因子（分散因子）活性の低分子モジュレーターの組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527675A JP2011527675A (ja) | 2011-11-04 |
| JP2011527675A5 true JP2011527675A5 (enExample) | 2012-08-23 |
| JP5775452B2 JP5775452B2 (ja) | 2015-09-09 |
Family
ID=41507639
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517424A Expired - Fee Related JP5775452B2 (ja) | 2008-07-10 | 2009-07-09 | 肝細胞増殖因子（分散因子）活性の低分子モジュレーターの組成物および方法 |
| JP2015012415A Pending JP2015108002A (ja) | 2008-07-10 | 2015-01-26 | 肝細胞増殖因子（分散因子）活性の低分子モジュレーターの組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012415A Pending JP2015108002A (ja) | 2008-07-10 | 2015-01-26 | 肝細胞増殖因子（分散因子）活性の低分子モジュレーターの組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US8772326B2 (enExample) |
| EP (1) | EP2313093A4 (enExample) |
| JP (2) | JP5775452B2 (enExample) |
| CN (1) | CN102149379A (enExample) |
| CA (1) | CA2767331A1 (enExample) |
| IL (1) | IL210544A (enExample) |
| WO (1) | WO2010005580A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2313093A4 (en) | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY |
| KR20120025524A (ko) | 2009-06-12 | 2012-03-15 | 스미토모 고무 고교 가부시키가이샤 | 차량 |
| CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| JP2014509297A (ja) * | 2010-10-05 | 2014-04-17 | アンジオン バイオメディカ コーポレイション | 肝細胞増殖因子（散乱因子）活性の小分子モジュレーターの使用方法 |
| RU2678830C2 (ru) | 2013-03-15 | 2019-02-04 | Версеон Корпорейшн | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз |
| KR20150130405A (ko) | 2013-03-15 | 2015-11-23 | 베르선 코포레이션 | 트롬빈의 억제제로서의 할로게노피라졸 |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| HK1246164A1 (zh) | 2015-02-27 | 2018-09-07 | Verseon Corporation | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| WO2018112816A1 (zh) * | 2016-12-22 | 2018-06-28 | 高雄医学大学 | (2r，4r)-1，2，4-三羟基十七碳-16-炔在制备预防或治疗肝损伤医药组合物中的应用 |
| KR20220004083A (ko) * | 2019-04-11 | 2022-01-11 | 앤지온 바이오메디카 코포레이션 | (e)-3-[2-(2-티에닐)비닐]-1h-피라졸의 고체 형태 |
| WO2021087392A1 (en) * | 2019-10-31 | 2021-05-06 | Angion Biomedica Corp. | Improving renal function after kidney transplantation |
| CN119504599B (zh) * | 2024-11-18 | 2025-09-26 | 安徽医科大学 | 一种用于治疗肾脏纤维化的吡唑类化合物及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE138770C (enExample) | ||||
| JPS48713Y1 (enExample) | 1967-12-19 | 1973-01-09 | ||
| DD138770A1 (de) | 1978-09-20 | 1979-11-21 | Juergen Liebscher | Verfahren zur herstellung von 5-styryl-pyrazolen und ihren vinylogen |
| US4806535A (en) | 1987-07-22 | 1989-02-21 | Rorer Pharmaceutical Corporation | Imidazolylphenyl and 1,2,4-triazolylphenyl benzopyridazinone and pyridopyridazinone compounds and their use for increasing cardiatonic contractility |
| JPH02193994A (ja) | 1989-01-23 | 1990-07-31 | Kyowa Hakko Kogyo Co Ltd | ピリダジノン誘導体 |
| US6566098B1 (en) | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
| JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
| ATE292476T1 (de) | 1995-08-29 | 2005-04-15 | Anges Mg Inc | Ein medikament,das hgf gen enthält |
| US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
| JPH11288112A (ja) | 1998-04-06 | 1999-10-19 | Mitsubishi Paper Mills Ltd | 電子写真感光体 |
| KR20010101675A (ko) | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6437006B1 (en) * | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
| WO2001034650A1 (en) | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Hgf-sf monoclonal antibody combinations |
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1355921A2 (en) * | 2000-06-29 | 2003-10-29 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| DE10047486A1 (de) * | 2000-09-26 | 2002-04-11 | Bayer Ag | Phenoxyphenyl Alkansulfonate |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| US6610726B2 (en) * | 2001-06-29 | 2003-08-26 | North Shore-Long Island Jewish Research Institute | Compositions and agents for modulating cellular proliferation and angiogenesis |
| US20030073692A1 (en) | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| NZ534378A (en) | 2002-02-22 | 2006-10-27 | Schering Corp | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same |
| WO2004009599A1 (en) | 2002-07-19 | 2004-01-29 | Targacept, Inc. | Five-membered heteroaromatic olefinic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of ncotinic cholinergic receptors |
| US7192976B2 (en) | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| FR2868519B1 (fr) * | 2004-03-30 | 2006-06-16 | Christian Muller | Generateur thermique a materiau magneto-calorique et procede de generation de thermies |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| WO2006036981A2 (en) | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Small molecule modulators of cytokine activity |
| US20110230407A1 (en) | 2005-03-14 | 2011-09-22 | Alexander Yuzhakov | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
| US7879898B1 (en) | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| US8193177B2 (en) | 2007-11-13 | 2012-06-05 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases |
| EP2313093A4 (en) | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY |
| US20110098304A1 (en) | 2008-10-22 | 2011-04-28 | Bijoy Panicker | Small molecule inhibitors of PARP activity |
| US20120190668A1 (en) | 2009-08-12 | 2012-07-26 | Oehlen Lambertus J W M | Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity |
| JP2014509297A (ja) | 2010-10-05 | 2014-04-17 | アンジオン バイオメディカ コーポレイション | 肝細胞増殖因子（散乱因子）活性の小分子モジュレーターの使用方法 |
-
2009
- 2009-07-09 EP EP09794828A patent/EP2313093A4/en not_active Withdrawn
- 2009-07-09 WO PCT/US2009/004014 patent/WO2010005580A2/en not_active Ceased
- 2009-07-09 US US13/003,514 patent/US8772326B2/en active Active
- 2009-07-09 CA CA2767331A patent/CA2767331A1/en not_active Abandoned
- 2009-07-09 CN CN2009801353421A patent/CN102149379A/zh active Pending
- 2009-07-09 JP JP2011517424A patent/JP5775452B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-10 IL IL210544A patent/IL210544A/en not_active IP Right Cessation
-
2014
- 2014-05-25 US US14/287,039 patent/US20140256727A1/en not_active Abandoned
-
2015
- 2015-01-26 JP JP2015012415A patent/JP2015108002A/ja active Pending
-
2017
- 2017-02-23 US US15/440,398 patent/US20180009793A1/en not_active Abandoned
-
2019
- 2019-01-04 US US16/239,836 patent/US10899750B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527675A5 (enExample) | ||
| JP2012529486A5 (enExample) | ||
| JP5775452B2 (ja) | 肝細胞増殖因子（分散因子）活性の低分子モジュレーターの組成物および方法 | |
| RU2469042C2 (ru) | Терапевтически активные триазолы и их использование | |
| JP5643213B2 (ja) | 肥大性心筋症治療用のホスホジエステラーゼタイプＩＩＩ（ＰＤＥＩＩＩ）インヒビターまたはＣａ２＋感作剤 | |
| US10988468B2 (en) | Nitrogen-containing 6-membered cyclic compound | |
| JPH11228410A (ja) | イミダゾールアンジオテンシン−ｉｉ受容体拮抗薬からなる慢性腎不全治療剤 | |
| CN107530352A (zh) | 使用茚满乙酸衍生物治疗肝病的方法 | |
| JP2006513221A5 (enExample) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| KR20140056250A (ko) | 좌심실 확장 기능 개선제 | |
| JP2014509297A5 (enExample) | ||
| EP2624830A2 (en) | Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
| JPWO1999040919A1 (ja) | 心拡張障害治療剤 | |
| JP2009286712A (ja) | スピロキノン化合物及び医薬組成物 | |
| JPH08165239A (ja) | 抗動脈硬化剤 | |
| JPWO2007069669A1 (ja) | アディポネクチン産生を増強する医薬組成物 |